MSD has welcomed the expanded PBS listing of KEYTRUDA (pembrolizumab) in combination with Eisai's LENVIMA (lenvatinib) for women with advanced, metastatic, or recurrent endometrial carcinoma. …
MSD welcomes new listing for Keytruda in combination with Eisai's Lenvima
June 2, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News -
Neurizon announces global agreement with Elanco for the commercialisation of NUZ-001
July 2, 2025 - - Australian Biotech -
Prescient Therapeutics opens share purchase plan
July 2, 2025 - - Australian Biotech -
Amplia Therapeutics announces additional confirmed partial response recorded in ACCENT trial
July 2, 2025 - - Australian Biotech -
Island Pharmaceuticals announces the appointment of new chair
July 2, 2025 - - Australian Biotech